Clare Ozawa

Dr. Ozawa is a managing director at Versant Ventures with a focus on investments in the Bay Area and San Diego. Previously, she was COO of Inception Sciences, where she was responsible for strategic business development, operations and finance for the Inception Sciences research sites in San Diego, Vancouver and Montreal. During her tenure at Inception, she assumed leadership roles in the creation and management of six new companies launched in partnership with academic researchers and major biopharmaceutical companies. Prior to Inception, Dr. Ozawa was an investment professional at Versant, where she was involved in several successful investments including Flexion (2014 IPO), BioTie (sale) and Quanticel (sale). Earlier in her career, she worked at Novartis Pharma in the Office of the CEO and was at McKinsey & Company. Dr. Ozawa earned her B.S. in biological sciences with honors and distinction from Stanford University, and a Ph.D. in neurosciences from Stanford University Medical School.